ABEONA THERAPEUTICS INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ABEONA THERAPEUTICS INC. (ABEO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$84.00 thousand for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-14
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$10.00K.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$74.00K.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$18.00K.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$148.00K.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$519.00K, a 115.31% decline from fiscal 2015.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $3.39M.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $0.00.
- ABEONA THERAPEUTICS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$2.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$84.00K 10-Q · filed 2017-08-14 | -$102.00K derived: sum of 3 quarters · filed 2017-08-14 | -$250.00K derived: sum of 4 quarters · filed 2017-08-14 |
| 2017-03-31 | -$74.00K 10-Q · filed 2017-05-15 | -$92.00K derived: sum of 2 quarters · filed 2017-05-15 | -$240.00K derived: sum of 3 quarters · filed 2017-05-15 | -$366.00K derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$166.00K derived: sum of 2 quarters · filed 2017-03-30 | -$292.00K derived: sum of 3 quarters · filed 2017-08-14 | -$519.00K 10-K · filed 2017-03-30 |
| 2016-09-30 | -$148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$274.00K derived: sum of 2 quarters · filed 2017-08-14 | -$501.00K 10-Q · filed 2016-11-14 | -$768.00K derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$353.00K 10-Q · filed 2017-08-14 | -$620.00K derived: sum of 3 quarters · filed 2017-08-14 | -$647.00K derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | -$227.00K 10-Q · filed 2017-05-15 | -$494.00K derived: sum of 2 quarters · filed 2017-05-15 | -$521.00K derived: sum of 3 quarters · filed 2017-05-15 | $3.17M derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$294.00K derived: sum of 2 quarters · filed 2017-03-30 | $3.40M derived: sum of 3 quarters · filed 2017-03-30 | $3.39M 10-K · filed 2017-03-30 |
| 2015-09-30 | -$27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $3.67M derived: sum of 2 quarters · filed 2016-11-14 | $3.66M 10-Q · filed 2016-11-14 | $3.66M derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $3.68M 10-Q · filed 2016-08-15 | $3.68M derived: sum of 3 quarters · filed 2016-08-15 | $3.68M derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | -$9.00K 10-Q · filed 2016-05-16 | -$9.00K derived: sum of 2 quarters · filed 2016-05-16 | -$9.00K derived: sum of 3 quarters · filed 2016-05-16 | -$9.00K derived: sum of 4 quarters · filed 2016-05-16 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $0.00 derived: sum of 3 quarters · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | $0.00 derived: sum of 2 quarters · filed 2015-11-16 | $0.00 10-Q · filed 2015-11-16 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $0.00 10-Q · filed 2015-08-14 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | -$2.00K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |